Melasma like hyperpigmentation on face: A rare side effect of imatinib

Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia. Keywords: Drug-induced pigmentation, Imatinib-mesylate, Melasma, Chronic myeloid leukemia.